rolipram has been researched along with E coli Infections in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " As a selective phosphodiesterase-4 inhibitor, rolipram also exhibits the abilities of inhibiting multiple pro-inflammatory cytokines production in macrophages and toxin-induced inflammation in mice." | 7.96 | Rolipram Protects Mice from Gram-negative Bacterium Escherichia coli-induced Inflammation and Septic Shock. ( Chen, X; Jiang, Y; Lu, X; Pan, ZK; Wang, J, 2020) |
| " As a selective phosphodiesterase-4 inhibitor, rolipram also exhibits the abilities of inhibiting multiple pro-inflammatory cytokines production in macrophages and toxin-induced inflammation in mice." | 3.96 | Rolipram Protects Mice from Gram-negative Bacterium Escherichia coli-induced Inflammation and Septic Shock. ( Chen, X; Jiang, Y; Lu, X; Pan, ZK; Wang, J, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lu, X | 1 |
| Wang, J | 1 |
| Chen, X | 1 |
| Jiang, Y | 1 |
| Pan, ZK | 1 |
| Okayama, A | 1 |
| Mikasa, K | 1 |
| Matsui, N | 1 |
| Higashi, N | 1 |
| Miyamoto, M | 1 |
| Kita, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)[NCT04570449] | Early Phase 1 | 0 participants (Actual) | Interventional | 2020-11-30 | Withdrawn (stopped due to Study timeline is not feasible) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for rolipram and E coli Infections
| Article | Year |
|---|---|
Rolipram Protects Mice from Gram-negative Bacterium Escherichia coli-induced Inflammation and Septic Shock.
Topics: Animals; Anti-Inflammatory Agents; Cytokines; Escherichia coli; Escherichia coli Infections; Inflamm | 2020 |
An interventional approach to block brain damage caused by Shiga toxin-producing Escherichia coli infection, by use of a combination of phosphodiesterase inhibitors.
Topics: Animals; Antigens, Tumor-Associated, Carbohydrate; Brain Diseases; Cecum; Cells, Cultured; Cytokines | 2004 |